World News: 12:00 GMT Wednesday 15th May 2019. [Matinas BioPharma Holdings, Inc. via Globe Newswire via SPi World News]
BEDMINSTER, N.J., May 15, 2019 (GLOBE NEWSWIRE) -- (NYSE AMER: MTNB), today announced that they have entered into a research collaboration with ViiV Healthcare, a global specialist HIV company established in November of 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in the treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV, to evaluate the use of Matinas’ lipid nano-crystal (“LNC”) platform delivery technology.
Formulations of select antivirals will be developed using Matinas’ LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Promising formulations will be tested in preclinical studies to identify a lead LNC-antiviral formulation to take forward in development.
“This is the second collaboration announced this year where we have been asked to pair our LNC platform delivery technology with molecules which could have a significant impact on disease burden. In working closely with industry leading pharma companies like ViiV, we are expanding the depth, breadth and utilization of our disruptive platform and positioning our technology to potentially solve complex issues related to intracellular delivery in the absence of undesirable toxicity,” said of Matinas. “We look forward to continuing to expand the application of our LNC technology to potentially transformative medicines for the benefit of patients in need.”
Matinas’ LNC platform delivery technology offers an intracellular drug delivery solution with potential advantages across a broad range of therapeutics. The Company has demonstrated in preclinical animal models the ability to formulate and thereby re-design a wide variety of molecules and drugs (including oligonucleotides, peptides, proteins, vaccines, and small molecules) which, (a) require delivery technology to improve the stability of molecules inside and outside of the body; (b) could benefit from efficient delivery and cellular uptake by target cells; (c) are currently only available in IV formulations or (d) otherwise experience significant toxicity-related adverse events.
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on creating value through the streamlined development of MAT9001 for the treatment of cardiovascular and metabolic conditions and the application of its lipid nano-crystal (“LNC”) platform technology to solve complex challenges relating to the safe and effective delivery of small molecules, gene therapies, proteins, peptides and vaccines.
The Company is actively pursuing the development of MAT9001 with the support of a world-class team of clinical key opinion leaders and regulatory consultants. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, which has shown superiority versus Vascepa (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoprotein CIII and PCSK9 levels.
In addition, the Company's proprietary, disruptive technology utilizes lipid nano-crystal cochleates to encapsulate small molecules, nucleic acid polymers, vaccines and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
For more information, please visit and connect with the Company on , and .
Source: Matinas BioPharma Holdings, Inc.
Globe Newswire: 12:00 GMT Wednesday 15th May 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.